# FDA recall D-1069-2019

> **Pfizer Inc.** · Class III · drug recall initiated 2019-03-15.

## Product

Cleocin Phosphate, clindamycin injection, USP, 900 mg/ 6 mL (150 mg/mL), 6 mL vial, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Pfizer, Inc, New York, NY 10017. NDC 0009-3447-01

## Reason for recall

Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

## Distribution

Nationwide USA and Guam

## Key facts

- **Recall number:** D-1069-2019
- **Recalling firm:** Pfizer Inc.
- **Classification:** Class III
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2019-03-15
- **Report date:** 2019-04-10
- **Termination date:** 2022-08-11

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** New York, NY, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1069-2019

## Citation

> AI Analytics. FDA recall D-1069-2019. Retrieved 2026-05-25 from https://api.ai-analytics.org/recall/D-1069-2019. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*